Ticker Details
Coherus BioSciences, Inc. Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.
IPO Date:	November 6, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$187.35M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 3.10%
Avg Daily Range (30 D):	$0.05 | 3.14%
Avg Daily Range (90 D):	$0.05 | 3.72%

Institutional Daily Volume
Avg Daily Volume:	1.1M
Avg Daily Volume (30 D):	1.04M
Avg Daily Volume (90 D):	1.07M

Trade Size
Avg Trade Size (Sh.):	154
Avg Trade Size (Sh.) (30 D):	264
Avg Trade Size (Sh.) (90 D):	284

Institutional Trades
Total Institutional Trades:	3,195
Avg Institutional Trade:	$1.5M
Avg Institutional Trade (30 D):	$.51M
Avg Institutional Trade (90 D):	$.67M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$.53M
Avg Closing Trade (90 D):	$.57M
Avg Closing Volume:	158.84K

News

Nov 6, 2025 @ 6:54 PM Arvind Sood joins Coherus Oncology as Chief Strate... Source: Denny Lanfear

Apr 1, 2025 @ 12:00 PM Coherus Announces Repurchase of Approximately $170... Source: Coherus Biosciences, Inc.

Jul 30, 2024 @ 5:00 PM Hepatic Tumor Clinical Trial Pipeline Experiences ... Source: Delveinsight

Jun 27, 2024 @ 12:26 PM Coherus BioSciences Announces Divestiture of YUSIM... Source: Coherus BioSciences, Inc.

Jun 23, 2024 @ 3:13 PM Pfizer: Seriously Undervalued At Peak Pessimism Source: ALLKA Research

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$1.33	$-.31	$2.57
Diluted EPS	$1.33	$-.31	$2.57
Revenue	$277.73M	$11.57M	$10.25M
Gross Profit	$156.38M	$7.85M	$6.86M
Net Income / Loss	$154.97M	$-35.53M	$297.77M
Operating Income / Loss	$-92.65M	$-44.33M	$-45.49M
Cost of Revenue	$121.35M	$3.72M	$3.4M
Net Cash Flow	$5.64M	$-113.56M	$134.48M
PE Ratio	1.24